Canopy Growth (CGC)

The company’s reported operations include Canadian cannabis, international cannabis markets, Storz & Bickel, and This Works. Its Canadian cannabis business serves the country’s legal recreational and medical channels and has historically been its largest revenue contributor. Internationally, Canopy targets selected medical cannabis opportunities in regulated markets, where patient access, licensing, and product rules vary by jurisdiction.

Storz & Bickel is a notable non-cultivation asset within the group. The Germany-based brand is known for premium vaporizer devices used by medical and consumer customers, including the Volcano product line. This Works adds a wellness and skincare component to the portfolio, broadening Canopy’s exposure beyond cannabis flower and extracts.

Canopy’s investment case is closely tied to the evolution of cannabis regulation, pricing, brand strength, production efficiency, and progress toward profitability. Like other cannabis companies, it operates in a sector shaped by changing consumer preferences, excise taxes, compliance costs, and limits on advertising and distribution. CGC stands out for its broad brand portfolio, international ambitions, and exposure to ancillary cannabis products, while remaining highly sensitive to developments in the Canadian market and global legalization trends.